

FluCov Influenza Activity Report #20

8 April 2024


Take home: decreasing influenza activity in the Northern Hemisphere

- North America and Europe:** The United States reports overall 9% influenza positivity, with minimal to low activity in most states, although some states still experience high activity. In Europe, influenza activity continued to decrease and has returned to baseline levels in most countries. In week 12/2024, Denmark, Italy, Spain and the UK report very low activity (<10% positivity), and France (14%) and Germany (18%) report low activity.
- Asia:** Influenza detections decreased in China. Overall positivity rate also decreased in week 13/2024, compared to week 12, with very low activity (<10% positivity) in Northern China and low activity (17% positivity) in Southern China.
- Circulating virus:** Globally, all seasonal influenza viruses except B/Yamagata are circulating. While B/Victoria predominated in China, the US and Canada, A(H1N1)pdm09 dominated circulation in Europe.
- Vaccine match:** US (CDC) reports that vaccine components are well-matched to circulating A(H1N1)pdm09, B/Victoria and A(H3) clades. The same is true for Europe (ECDC) with the exception that some A(H3) viruses (2a.3a.1 clade) are less well-matched (ERVISS).
- Influenza Viruses of Pandemic Potential:** On 7 April, the first case of influenza A(H9) ever reported in Vietnam was identified in a 37-year-old man with severe pneumonia; subgroup determination and contact tracing is ongoing. H9N2 only causes mild symptoms in poultry; 98 H9N2 cases including two deaths have been reported since 2015 (Promed).
- COVID hospitalizations:** Continued to decrease in the EU, England and the US, after a peak around the end of 2023.

Positive Influenza tests (%)


Note: the positivity rate graph for Denmark was last updated week 12/2024

— Season 2023/2024
 — Season 2022/2023
 — Season 2021/2022
 — Average of pre-COVID-19 seasons (2014/2015 to 2018/2019) [Min; Max]



Weekly COVID-19 hospital admissions

(England, EU/EEA, US – admissions/100,000)



Displayed data is the most recent reported; it is possible that there may be a delay in reporting. Countries & inclusion dates for EU/EEA data vary markedly each week.

Data sources & details

China:	China CDC
US:	FluView (Clinical Laboratories)
Spain:	ERVISS
DK:	WHO FluNET (non-sentinel)
All others:	WHO FluNet (sentinel)
COVID:	US (Department of Health and Human Services) EU (ERVISS), England (UKHSA)
Vaccine match:	US (CDC), EU (ERVISS)

A Nivel publication

FluCov team: Susanne Heemskerk, Bronke Boudewijns, Marco Del Riccio, Daan van Kooten, Saverio Caini, Caroline Schneeberger.

[FluCov Influenza Activity Report #20: 8 April 2024](#). Netherlands, Utrecht: Nivel, 2024

Websites for more information

Project Website: <https://www.nivel.nl/en/flucoV>

FluCoV Dashboard: <https://www.nivel.nl/en/flucoV-dashboard>

Funding

The Nivel FluCov project is funded by Sanofi